Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

Protection against oncogenic non-vaccine types (cross-protection) offered by human papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical efficacy data suggest the two licensed vaccines [HPV-16/18 vaccine, GlaxoSmithKline Biologicals (GSK), and HPV-6/11/16/18 vac...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Einstein, Mark H, Baron, Mira, Levin, Myron J, Chatterjee, Archana, Fox, Bradley, Scholar, Sofia, Rosen, Jeffrey, Chakhtoura, Nahida, Lebacq, Marie, van der Most, Robbert, Moris, Philippe, Giannini, Sandra L, Schuind, Anne, Datta, Sanjoy K, Descamps, Dominique
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2011
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3338933/
https://ncbi.nlm.nih.gov/pubmed/22048172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.12.18282
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky